What is the recommended treatment for Helicobacter pylori (H. pylori) infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

H. pylori Treatment Recommendations

Bismuth quadruple therapy for 14 days is the preferred first-line treatment for H. pylori infection when antibiotic susceptibility is unknown. 1, 2

First-Line Treatment Options

Preferred Regimen: Bismuth Quadruple Therapy (14 days)

  • PPI (twice daily)
  • Bismuth subsalicylate/subcitrate
  • Tetracycline
  • Metronidazole
  • Expected eradication rate: 85% 1

Alternative First-Line Options:

  1. In areas with low clarithromycin resistance (<15%):

    • Triple therapy: PPI + Clarithromycin + Amoxicillin for 14 days 1, 3
  2. For patients with penicillin allergy:

    • Bismuth quadruple therapy (as above) 1
  3. FDA-approved regimens 4:

    • Triple therapy: 1g amoxicillin, 500mg clarithromycin, and 30mg lansoprazole, all twice daily for 14 days
    • Dual therapy: 1g amoxicillin and 30mg lansoprazole, each three times daily for 14 days (for patients allergic/intolerant to clarithromycin)

Second-Line Treatment Options

If first-line therapy fails, recommended options include:

  1. Levofloxacin-based triple therapy (14 days):

    • PPI (twice daily)
    • Levofloxacin
    • Amoxicillin 1, 5
  2. Bismuth quadruple therapy (14 days):

    • If not used as first-line treatment 1, 2

Third-Line Treatment Options

For patients with multiple treatment failures:

  1. Antimicrobial susceptibility testing (AST) should guide therapy when available 3, 2

  2. If AST unavailable:

    • Use antibiotics not previously used or with low likelihood of resistance
    • Options include rifabutin-based regimens 2, 6
    • Levofloxacin-based rescue therapy has shown 60-66% eradication rates as third-line therapy 5

Important Considerations

Administration Guidelines

  • Take medications at the start of meals to minimize gastrointestinal intolerance 4
  • Patient counseling is essential:
    • Warn about darkening of stool from bismuth
    • Advise avoiding alcohol while taking metronidazole (disulfiram-like reaction)
    • Stress importance of completing full course 1

Testing for Eradication

  • Test for eradication at least 4 weeks after completing treatment 1
  • Use urea breath test or monoclonal stool antigen test
  • Stop PPI at least 2 weeks before testing 1

Special Populations

  • Renal impairment: Adjust amoxicillin dosage for severe renal impairment (GFR <30 mL/min) 4
  • Pregnancy: Avoid invasive diagnostic procedures unless absolutely necessary 1

Treatment Pitfalls to Avoid

  • Don't use clarithromycin-containing regimens in areas with high clarithromycin resistance (≥15%) without susceptibility testing 7
  • Don't forget to test for eradication after treatment completion
  • Don't use antibiotics previously failed without susceptibility testing
  • Poor compliance significantly reduces eradication rates; patient education is crucial 1

By following these evidence-based recommendations, H. pylori infection can be effectively treated, reducing the risk of complications such as peptic ulcer disease and gastric cancer.

References

Guideline

H. pylori Eradication Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.

The American journal of gastroenterology, 2024

Research

Management of Helicobacter pylori infection.

JGH open : an open access journal of gastroenterology and hepatology, 2023

Research

Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.